An Open-label, Single Dose, Mass Balance Study to Assess the Disposition of [14C]-NV-5138 in Healthy Male Subjects
Latest Information Update: 17 Mar 2022
At a glance
- Drugs NV-5138 (Primary)
- Indications Depressive disorders
- Focus Pharmacokinetics
- Sponsors Navitor Pharmaceuticals
- 12 Mar 2022 Status changed from recruiting to completed.
- 13 Dec 2021 New trial record